


What is claimed is:

1. A compound of Formula (I)




including salts, solvates, and pharmaceutically acceptable derivatives thereof,

wherein A is H, alkyl, or aryl;

R¹ is D¹, D², D³, D⁴, or D⁵,

wherein D¹ is



and R³ and R⁴ are each independently H, alkyl, alkylsulfonyl, or -C(O)-(CH₂)_x-R⁵,


where R⁵ is alkyl, acyl, alkoxy, -(O)-(CH₂)_x-(O)-alkyl, or -NR⁶R⁷,

where R⁶ and R⁷ are each independently H or alkyl, or

R^6 and R^7 combine to form a 5- or 6-membered ring, optionally containing one or more additional heteroatoms, optionally containing one or more degrees of unsaturation, and optionally substituted one or more times with alkyl, hydroxy, carboxy, acyl, alkoxy, or halogen,

or R^3 and R^4 combine to form a 5- or 6-membered ring, optionally containing one or more additional heteroatoms, optionally containing one or more degrees of unsaturation, and optionally substituted one or more times with alkyl, hydroxy, carboxy, alkoxy, acyl, or halogen;

wherein D^2 is




and R^8 is alkyl, or $-\text{NR}^9\text{R}^{10}$,

where R^9 and R^{10} are each independently selected from H, alkyl, or $-(\text{CH}_2)_x-$ NR^6R^7 ,

where R^6 and R^7 are each independently H or alkyl,

or R^6 and R^7 combine to form a 5- or 6-membered ring, optionally containing one or more additional heteroatoms, optionally containing one or more degrees of unsaturation, and optionally substituted one or more times with alkyl, hydroxy, carboxy, acyl, alkoxy, or halogen;

wherein D^3 is



and

the dashed line represents an optional double bond;

when R¹¹ is -(CH₂)_x, the optional dashed double bond does not exist, and R¹² is alkylsulfonyl or -NR¹³R¹⁴,


where R¹³ and R¹⁴ are each independently selected from H, alkyl, -(CH₂)_x-R¹⁷, where R¹⁷ is alkoxy or -NR¹⁵R¹⁶,

where R¹⁵ and R¹⁶ are each independently H or alkyl,

or R¹³ and R¹⁴ combine to form a 5- or 6-membered ring, optionally containing one or more additional heteroatoms, optionally containing one or more degrees of unsaturation, and optionally substituted one or more times with alkyl or -(CH₂)_x-OH;

when R¹¹ is -(CH)-, the optional dashed double bond exists, and R¹² is -(CH)-C(O)-OH;

wherein D⁴ is



and R¹⁷ is hydroxy, alkoxy, or -NR¹⁸R¹⁹,

where R¹⁸ and R¹⁹ are each independently selected from H, alkyl, -(CH₂)_x-R²⁰,

where R²⁰ is alkylsulfonyl, hydroxy, aryl said aryl optionally substituted with hydroxy or alkoxy, heteroaryl, or -NR²¹R²²,

where R²¹ and R²² are each independently selected from H, acyl, alkyl,

or R²¹ and R²² combine to form a 5- or 6-membered ring, optionally containing one or more additional heteroatoms, optionally containing one or more degrees of unsaturation, and optionally substituted with alkyl or -(CH₂)_x-OH;

or R¹⁸ and R¹⁹ combine to form a 5- or 6-membered ring, optionally containing one or more additional heteroatoms, optionally containing one or more degrees of unsaturation, and optionally substituted with -(CH₂)_x-R²³,

where R²³ is alkoxy, hydroxy, -C(O)-R²⁴, where R²⁴ is a 5- or 6-membered ring optionally containing one or more heteroatoms and optionally containing one or more degrees of unsaturation, or -NR²⁵R²⁶, where R²⁵ and R²⁶ are each independently H or alkyl;

wherein D⁵ is

a 5- or 6- membered ring, optionally containing one or more heteroatoms, optionally containing one or more degrees of unsaturation, optionally fused with an additional 5- or 6- membered ring that optionally contains one or more heteroatoms and optionally contains one or more degrees of unsaturation,

wherein the ring or fused ring system may be optionally substituted one or more times with halogen, alkyl, haloalkyl, alkylsulfonyl, alkylthio, hydroxy, alkoxy, oxo, sulfonyl, sulfate ion, nitro, cyano, carboxy, alkoxycarbonyl, aryl where said aryl may be optionally substituted with sulfamoyl, heteroaryl where said heteroaryl may be optionally substituted with alkyl, or -NR²⁷R²⁸,

where R^{27} and R^{28} are each independently H, alkyl, acyl, alkoxy, alkoxy carbonyl, carboxy, or $-(CH_2)_x-NR^{29}R^{30}$, where R^{29} and R^{30} are each independently selected from H and alkyl,

or R^{27} and R^{28} combine to form a 5- or 6-membered ring, optionally containing one or more additional heteroatoms, optionally containing one or more degrees of unsaturation, and optionally substituted one or more times with alkyl, hydroxy, carboxy, acyl, alkoxy, or halogen,

or $-(O)_y-(CH_2)_x-R^{31}$, where R^{31} is hydroxy, alkoxy, haloalkyl, aryl optionally substituted with halogen, or $-NR^{27}R^{28}$, where R^{27} and R^{28} are as defined above;

wherein for each occurrence, x independently is 0, 1, 2, or 3;

wherein for each occurrence, y independently is 0 or 1; and

and R^2 is heteroaryl substituted one or more times with alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, nitro, or $-NR^{31}R^{32}$, wherein R^{31} and R^{32} are each independently selected from H and alkyl.


2. The compound of claim 1 wherein R^2 is pyridinyl.
3. The compound of claim 2 wherein R^2 is pyridinyl substituted with alkoxy.
4. The compound of claim 3 wherein the alkoxy is methoxy.
5. The compound of claim 2 wherein the pyridyl is 2-pyridyl.

6. The compound of claim 2 wherein the pyridyl is 3-pyridyl.
7. The compound of claim 2 wherein the pyridyl is 4-pyridyl.
8. The compound of claim 1 wherein R² is thiazolyl.
9. The compound of claim 1 wherein R² is benzimidazolyl.
10. The compound of claim 1 wherein A is H.
11. A pharmaceutical composition comprising:
a therapeutically effective amount of a compound as claimed in claims 1 to 9.
12. The pharmaceutical composition of claim 10 further comprising:
one or more of pharmaceutically acceptable carriers, diluents, or excipients.
13. A method of treating a disorder in a mammal, said disorder being
characterized by misregulation of one or more protein kinase comprising:

administering to said mammal a therapeutically effective amount of a
compound as claimed in claims 1 to 9.
14. The method of claim 12 wherein the kinase is a serine/threonine kinase.
15. The method of claim 13 wherein the kinase is GSK3.
16. A compound as claimed in claims 1 to 9 for use in therapy.
17. Use of a compound as claimed in claims 1 to 9 in the preparation of a
medicament for use in the treatment of a disorder characterized by
misregulation of one or more protein kinase.

18. A method of treating type 2 diabetes, hyperlipidemia, obesity, CNS disorders, neurotraumatic injuries, immune potentiation, baldness or hair loss, atherosclerotic cardiovascular disease, hypertension, polycystic ovary syndrome, ischemia, immunodeficiency, and cancer, comprising:
administering to said mammal a therapeutically effective amount of a compound as claimed in claims 1 to 9.
19. A method of treating type II diabetes, comprising:
administering to said mammal therapeutically effective amounts of a compound as claimed in claims 1 to 9; and
at least one additional anti-diabetic agent.
20. A compound according to any of claims 1- 9 with reference to any of the Examples.

21. A compound of Formula (II):



including salts, solvates, and pharmaceutically functional derivatives thereof,
where A is H, alkyl, or aryl; and

R^a is heteroaryl substituted one or more times with alkyl, alkoxy, halogen, haloalkyl,
haloalkoxy, nitro, or -NR^bR^c, wherein R^b and R^c are each independently selected from H
and alkyl.


22. The compound of claim 22 wherein A is H.

23. The compound of claim 23 wherein R^a is selected from 2-pyridyl, thiazolyl, or
benzimidazolyl.

24. The compound of claim 24 wherein R^a is 2-pyridyl substituted with alkoxy.

25. The compound of claim 25 wherein the alkoxy is methoxy.

26. A compound of formula (III)



including salts, solvates, and pharmaceutically functional derivatives thereof,

where A is H, alkyl, or aryl; and

R^a is heteroaryl substituted one or more times with alkyl, alkoxy, halogen, haloalkyl,
haloalkoxy, nitro, or -NR^bR^c, wherein R^b and R^c are each independently selected from H
and alkyl.


27. The compound of claim 27 wherein A is H.

28. The compound of claim 28 wherein R^a is selected from pyridyl, thiazolyl, or
benzimidazolyl.

29. The compound of claim 29 wherein R^a is pyridyl substituted with alkoxy.

30. The compound of claim 30 wherein the alkoxy is methoxy.

31. A compound of formula (IV)



including salts, solvates, and pharmaceutically functional derivatives thereof,

where A is H, alkyl, or aryl; and


R^a is heteroaryl substituted one or more times with alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, nitro, or -NR^bR^c, wherein R^b and R^c are each independently selected from H and alkyl.

32. The compound of claim 32 wherein A is H.

33. The compound of claim 33 wherein R^a is selected from pyridyl, thiazolyl, or benzimidazolyl.34. The compound of claim 34 wherein R^a is pyridyl substituted with alkoxy.

35. The compound of claim 35 wherein the alkoxy is methoxy.

36. A compound of formula (V)



including salts, solvates, and pharmaceutically functional derivatives thereof,

where A is H, alkyl, or aryl; and

R^a is heteroaryl substituted one or more times with alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, nitro, or -NR^bR^c, wherein R^b and R^c are each independently selected from H and alkyl.

37. The compound of claim 37 wherein A is H.

38. The compound of claim 38 wherein R^a is selected from pyridyl, thiazolyl, or benzimidazolyl.
39. The compound of claim 39 wherein R^a is pyridyl substituted with alkoxy.
40. The compound of claim 40 wherein the alkoxy is methoxy.